author-photo

Ashraf Badros

University of Maryland, College Park

16

Papers

471

Citations

Citation Trend

Filter By

Papers (8) Sort By

Journal Conference Others

Long-term remissions after stopping pembrolizumab for relapsed or refractory multiple myeloma

2019 Blood Advances
Show All
- Source
- Cite
- Save
Citations (7)
Plasma Cell Leukemia (PCL): Clinical Characteristics, Outcomes, and the Impact of Circulating Plasma Cells (CPC) Percentage — A Single Center Experience

2017 Blood
Show All
- Source
- Cite
- Save
Citations (1)
Pembrolizumab, pomalidomide and low dose dexamethasone for relapsed/refractory multiple myeloma

2017 Blood
Show All
- Source
- Cite
- Save
Citations (137)
Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214)

2017 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (13)
Single center experience with total body irradiation and melphalan (TBI-MEL) myeloablative conditioning regimen for allogeneic stem cell transplantation (SCT) in patients with refractory hematologic malignancies

2014 Annals of Hematology
Show All
- Source
- Cite
- Save
Citations (3)
Phase I trial of vorinostat plus bortezomib (bort) in relapsed/refractory multiple myeloma (mm) patients (pts)

2008 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (21)
PET/CT and MR imaging in myeloma

2007 Skeletal Radiology
- Michael E. Mulligan
- Ashraf Badros
Show All
- Source
- Cite
- Save
Citations (61)
Phase II Study of G3139, a Bcl-2 Antisense Oligonucleotide, in Combination With Dexamethasone and Thalidomide in Relapsed Multiple Myeloma Patients

2005 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (91)